Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)

Market Cap	6.44B +140.0%
Revenue (ttm)	59.56M -65.6%
Net Income	-162.45M
EPS	-0.21
Shares Out	784.94M
PE Ratio	n/a
Forward PE	13.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,160,600
Average Volume	3,682,454
Open	8.20
Previous Close	8.20
Day's Range	7.95 - 8.25
52-Week Range	3.05 - 11.80
Beta	0.43
RSI	69.61
Earnings Date	May 29, 2026

About HKG:1167

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications, including PDAC, CRC, and NSCLC; JAB-2485 Aurora A inhibitor, JAB-30355 p53 Y220C re...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 196
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1167

Financial Performance

In 2025, HKG:1167's revenue was 53.53 million, a decrease of -65.62% compared to the previous year's 155.71 million. Losses were -145.98 million, -6.25% less than in 2024.

Financial numbers in CNY